/RXEI

RXEI Stock - RxElite, Inc.

Q: What is the analyst price target for RXEI?

Analyst price target information is not currently available for RXEI.

Q: What is RXEI's market cap?

Market capitalization information is not currently available for RXEI.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RXEI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2004

FY2005

FY2006

FY2007

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta6.40

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2007	FY2006	FY2005	FY2004
Revenue	$2.81M	$1.18M	$966,490	$835,076
Gross Profit	$144,000	$741,951	$517,002	$835,076
Gross Margin	5.1%	63.1%	53.5%	100.0%
Operating Income	$12.28M	$143,986	$35,904	$835,076
Net Income	$-17,165,275	$93,986	$-35,904	$-34,300
Net Margin	-610.5%	8.0%	-3.7%	-4.1%
EPS	$-0.27	$0.01	$-0.00	$0.00

Company Overview

RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia. Its customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. The company has partnership agreements with Stason Pharmaceuticals, Inc.; Alkem Laboratories Limited; and Zach Systems S.p.A. RxElite is headquartered in Meridian, Idaho. RxElite Inc. operates as a subsidiary of Piramal Healthcare Ltd.

Visit Website

Frequently Asked Questions about RXEI

What is RXEI's current stock price?

RxElite, Inc. (RXEI) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for RXEI?

No analyst price targets are currently available for this stock.

What sector is RxElite, Inc. in?

RxElite, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is RXEI's market cap?

RxElite, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does RXEI pay dividends?

No, RxElite, Inc. does not currently pay a dividend to shareholders.